EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores

Andreas Wollenberg iD, Dagmar Simon iD, Kanokvalai Kulthanan iD, Ignasi Figueras-Nart iD, Laurent Misery iD, Nithi Tangsirisap iD, Lara Spina iD, Na Lu iD, Susanne Grond iD, Kilian Eyerich iD

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19669 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Andreas Wollenberg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Eczema, Azetidines, Purines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Baricitinib treatment in adults with moderate‐to‐severe atopic dermatitis (AD) has demonstrated rapid improvements in itch as well as AD sign severity and affected body surface area as assessed by the Eczema Area and Severity Index (EASI) total score, whether administered as monotherapy or in combination with topical corticosteroids (TCS). As EASI clinical signs differ in time course and associated antecedents, the effects of baricitinib on each individual clinical sign are of interest.

Objectives

In this post hoc analysis, we aimed to investigate the effects of baricitinib on individual EASI subscores, namely excoriation, oedema/papulation, erythema and lichenification, in both monotherapy and TCS combination therapy trials.

Methods

We analysed the percent change from baseline in individual EASI subscores from three phase‐III, double‐blind, 16‐week trials of baricitinib in monotherapy (BREEZE‐AD1/BREEZE‐AD2) and TCS combination therapy (BREEZE‐AD7) cohorts via mixed model repeated measures (MMRM).

Results

Baricitinib 4 mg showed rapid and sustained improvements in all four clinical signs in both cohorts. Significant effects emerged at week 1 for excoriation, oedema/papulation and erythema scores in monotherapy ( p < 0.001) and TCS combination therapy ( p < 0.001, p < 0.01, p < 0.001), plateaued at week 4, and remained significant versus placebo through week 16. The effect on lichenification scores also emerged early, at week 1 in monotherapy ( p < 0.05) and week 2 in combination therapy ( p < 0.001), with scores continuously improving without a clear plateau. Effect magnitude was highest in excoriation scores, exhibiting near‐maximal reduction in week 1 of monotherapy and remaining highest across all timepoints in combination therapy.

Conclusions

Rapid and sustained improvements were observed across clinical signs of inflammation and particularly on excoriation following baricitinib treatment. Our findings suggest that selective inhibition of janus kinases 1 and 2 leads to rapid and sustained control of skin inflammation, and that rapid reductions in itch translate into early disruption of the itch‐scratch cycle.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicEczemaAzetidinesPurinesPyrazolesSulfonamidesAdultHumansPruritusInflammationErythemaEdemaSeverity of Illness IndexDouble-Blind MethodTreatment Outcome

Substanzen

baricitinibAzetidinesPurinesPyrazolesSulfonamides

Autor:innen und Institutionen

  • Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, Munich, Germany.
  • Department of Dermatology and Allergy, Augsburg University Hospital, Augsburg, Germany.
  • Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Berne, Switzerland.
  • Allergy and Immunology Unit, Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Dermatology, Hospital Universitari de Bellvitge, University of Barcelona, Barcelona, Spain.
  • Department of Dermatology, Venereology, and Allergology and French Expert Centre on Pruritus, University Hospital of Brest, Brest, France.

ORCID-Profile: Andreas Wollenberg, Dagmar Simon, Kanokvalai Kulthanan, Ignasi Figueras-Nart, Laurent Misery, Nithi Tangsirisap, Lara Spina, Na Lu, Susanne Grond, Kilian Eyerich

Förderung

  • Eli Lilly and Company

Zitieren

APA

Wollenberg, A., Simon, D., Kulthanan, K., Figueras-Nart, I., Misery, L., Tangsirisap, N., Spina, L., Lu, N., Grond, S., & Eyerich, K. (2024). Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19669

Vancouver

Wollenberg A, Simon D, Kulthanan K, Figueras-Nart I, Misery L, Tangsirisap N, et al. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19669

BibTeX
@article{Wollenberg2024,
  author = {Wollenberg, Andreas and Simon, Dagmar and Kulthanan, Kanokvalai and Figueras-Nart, Ignasi and Misery, Laurent and Tangsirisap, Nithi and Spina, Lara and Lu, Na and Grond, Susanne and Eyerich, Kilian},
  title = {Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19669}
}
Kostenlos starten →